Jonathan Glass, M.D.
Jonathan D. Glass, M.D., is the director of the Emory ALS Center and the division of neuromuscular diseases in the department of neurology at Emory University in Atlanta. He is widely known for his research on the pathogenesis and prevention of axonal degeneration in neurological diseases, and for his work in human and experimental neuropathology. His laboratory currently focuses on the role of axonal degeneration in animal models of ALS as well as on proteomic biomarkers of ALS in animals and in humans. Dr. Glass is also the principle investigator for the current phase 1 study of spinal cord injection of spinal cord derived neural progenitor cells for patients with ALS (funded by Neuralstem, Inc.). Dr. Glass is an active clinician who has been cited each year since 2001 as one of “America’s Top Doctors” (Castle Connolly Medical) and since 2005 as one of the very few neurologists in “Atlanta’s Top Doctors” (Atlanta Magazine). A teacher and mentor to young physicians, he served as the director of Emory’s neurology residency program from 2001 to 2006. Dr. Glass received his undergraduate degree from Middlebury College (Vermont) and his M.D. from the University of Vermont. He trained in neurology and neuropathology at Johns Hopkins, where he was a faculty member until moving to Emory in 1996.
The Promise and the Reality of Stem-Cell Therapies for Neurodegenerative Diseases
Jonathan D. Glass, M.D., is leading a clinical trial testing the safety of using adult stem cells to treat patients with amyotrophic lateral sclerosis (ALS), a neurodegenerative disease that remains untreatable. This trial, along with others like it, is just the beginning of a time-intensive process necessary to determine whether the benefits of stem-cell treatments—if there prove to be any—outweigh the risks. See also Commentary on this article, by Vassilis E. Koliatsos, M.D., and Leyan Xu, M.D., Ph.D.